

LOOKBRITE CREAM

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

Abbreviated Prescribing information for Lookbrite (Hydroquinone 2 % + Tretinoin 0.025 % + Mometasone Furoate 0.1 % Cream) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Hydroquinone is classified therapeutically as a depigmentation agent. Tretinoin is classified as keratolytic agent. Mometasone furoate like other topical corticosteroids has anti-inflammatory, anti-pruritic, and vasoconstrictive properties.

INDICATION: For short term intermittent treatment of moderate to severe melasma of the face in the presence of measures for sun avoidance including use of sun screen. **DIRECTION FOR**

USE: Lookbrite cream should be applied preferably once daily, in the evening. Duration of application would be determined by the physician, depending on the response.

CONTRAINDICATION: Lookbrite cream is contra-indicated in those patients with prior history of allergic reaction to hydroquinone, tretinoin and mometasone furoate. **WARNINGS &**

PRECAUTIONS: Caution should be exercised when Lookbrite cream is administered to nursing mothers. Lookbrite cream is strictly for external use only. Avoid contact with eyes, mouth and mucous membranes. Exposure to sunlight or ultra-violet light will cause repigmentation of bleached areas. **ADVERSE REACTIONS:** Dryness, fissuring of paranasal and infraorbital areas, erythema and stinging. Occasional hyper-sensitivity may develop.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

IN/LOOKBRITE CREAM /FEB 2015/01/AbPI

(Additional information is available on request)